TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06215716: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatoh

Sponsor: Akero Therapeutics, Inc · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1650 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$5,704,424

Rescue Site Savings

+$3,771,520

Unlock Full NCT06215716 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06215716 Rescue Dossier →